menu
    • menu

    Company profile for Vicebio

    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Vicebio is developing novel vaccines with the aim of best-in-class efficacy and ready-to-use fully liquid formulations. Its unique Molecular Clamp technology is able to lock viral surface proteins into the optimal conformation for high immunogenicity, stability and manufacturing productivity, enabling the design of ready-to-use multivalent vaccines targeting life-threatening viruses. The Company's initial focus is on respirato...
    Vicebio is developing novel vaccines with the aim of best-in-class efficacy and ready-to-use fully liquid formulations. Its unique Molecular Clamp technology is able to lock viral surface proteins into the optimal conformation for high immunogenicity, stability and manufacturing productivity, enabling the design of ready-to-use multivalent vaccines targeting life-threatening viruses. The Company's initial focus is on respiratory syncytial virus (RSV) targeting start of clinical studies in 2023.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Vicebiounitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    2nd Floor 168 Shoreditch High Street, London E1 6RA
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vicebio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi completes acquisition of Vicebio
    Sanofi completes acquisition of Vicebio

    05 Dec 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-12-04-10-00-00-3199555

    PRESS RELEASE
    05 Dec 2025
    Share Share
    Sanofi to Buy Respiratory Vaccine Biotech Vicebio for $1.6 B
    Sanofi to Buy Respiratory Vaccine Biotech Vicebio for $1.6 B

    23 Jul 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-07-22-05-30-00-3119150

    PRESS RELEASE
    23 Jul 2025
    Share Share
    Vicebio Advances RSV/hMPV Vaccine Study & Strengthens Board
    Vicebio Advances RSV/hMPV Vaccine Study & Strengthens Board

    21 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vicebio-advances-clinical-study-of-rsvhmpv-bivalent-vaccine--strengthens-board-with-appointments-of-world-class-veterans-302311876.html

    PR NEWSWIRE
    21 Nov 2024
    Share Share
    Vicebio Announces $100 Million Series B Financing for Vaccine
    Vicebio Announces $100 Million Series B Financing for Vaccine

    23 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vicebio-announces-100-million-series-b-financing-and-initiation-of-phase-1-clinical-study-of-rsvhmpv-bivalent-vaccine-302254783.html

    PR NEWSWIRE
    23 Sep 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search